Logo

Cytox VariaTect SNP Array

Jul 22, 2016

Cytox has launched its VariaTect genetic biomarker test for assessing Alzheimer's disease risk. The array, developed for research use, offers a simple blood-based test that provides a comprehensive panel of AD-informative SNPs to assist in research and novel drug discovery studies. It uses a combination of whole exome association analysis, variants identified through genome wide association studies, and variants considered to be of importance in AD-associated biological pathways. This includes approximately 130,000 novel and known SNP variants in gene pathways implicated in AD aetiology. The test was developed in partnership with Thermo Fisher Scientific subsidiary Affymetrix, and will be marketed as the Axiom Dementia Research array.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.